Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alisertib + Osimertinib in Metastatic EGFR-mutant Lung Cancer
NCT04085315Phase 1Completed
- Start
- Nov 2019
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of alisertib in non-small cell lung cancer (NSCLC) (4 arms). Primary endpoints: Maximum Tolerated Dose at 28 days, Dose Limiting Toxicity at 28 days and 1 more. Started Nov 2019; status: completed.
02
Drugs
alisertib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04085315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04085315.